Future oncology最新文献_第4页

Treatment options in hormone-sensitive prostate cancer: targeting the androgen-sensitive pathway. 激素敏感前列腺癌的治疗选择：针对雄激素敏感途径。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-10-03 DOI: 10.1080/14796694.2025.2561320

Cora N Sternberg, Alicia K Morgans

引用次数: 0

New strategies to enhance the efficacy of PD-1/PD-L1 inhibitors in treating microsatellite stable colorectal cancer. 提高PD-1/PD-L1抑制剂治疗微卫星稳定型结直肠癌疗效的新策略

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-09-11 DOI: 10.1080/14796694.2025.2558287

Yuhan Chen, Dong Tang

{"title":"New strategies to enhance the efficacy of PD-1/PD-L1 inhibitors in treating microsatellite stable colorectal cancer.","authors":"Yuhan Chen, Dong Tang","doi":"10.1080/14796694.2025.2558287","DOIUrl":"10.1080/14796694.2025.2558287","url":null,"abstract":"Immune checkpoint therapy has demonstrated significant potential in the treatment of various solid tumors. Among these, tumor-induced immunosuppression mediated by programmed cell death protein 1 (PD-1) represents a critical checkpoint. PD-1/programmed death-ligand 1 (PD-L1) inhibitors have been proven to exhibit substantial efficacy in solid tumors such as melanoma and bladder cancer. In colorectal cancer (CRC) treatment, their therapeutic effect is more pronounced in \"hot\" tumors compared to \"cold\" tumors with proficient mismatch repair (pMMR) and microsatellite stable (MSS) characteristics. However, only approximately 15% of CRC patients exhibit microsatellite instability-high (MSI-H) features. Consequently, to facilitate the conversion of \"cold\" tumors into \"hot\" tumors, this study found that combination treatment plans involving PD-1/PD-L1 inhibitors alongside chemotherapy, radiotherapy, targeted therapy, and anti-angiogenic drugs yield superior outcomes compared to monotherapy. This review focuses on recent research advancements in enhancing the immunotherapeutic efficacy of PD-1/PD-L1 inhibitors in MSS CRC, while systematically elucidating the mechanisms of immune resistance in MSS-type \"cold\" tumors and their potential therapeutic targets.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3207-3225"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12520087/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145033186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Managing side effects of talquetamab for relapsed/ refractory multiple myeloma in MonumenTAL- 1: a plain language summary. talquetamab治疗复发/难治性多发性骨髓瘤的副作用管理：一个简单的语言总结。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-09-15 DOI: 10.1080/14796694.2025.2555170

Ajai Chari, Samantha Shenoy, Sandy Kruyswijk, Brandi Hilder, Lisa O'Rourke, Niels W C J van de Donk

引用次数: 0

Plain language summary of IMerge, a Phase 3 study of imetelstat versus placebo in people with lower-risk myelodysplastic syndromes and anemia. IMerge是一项在低风险骨髓增生异常综合征和贫血患者中使用依美特司他与安慰剂对照的3期研究。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-10-12 DOI: 10.1080/14796694.2025.2565877

Rami S Komrokji

引用次数: 0

A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant. CEPHEUS研究达拉单抗联合硼替佐米、来那度胺和地塞米松用于新诊断的多发性骨髓瘤患者，这些患者预计不会接受干细胞移植。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-10-07 DOI: 10.1080/14796694.2025.2560134

Saad Z Usmani, Thierry Facon, Vania Hungria, Nizar J Bahlis, Christopher P Venner, Marc Braunstein, Ludek Pour, Josep M Martí, Supratik Basu, Yael C Cohen, Morio Matsumoto, Kenshi Suzuki, Cyrille Hulin, Sebastian Grosicki, Wojciech Legiec, Meral Beksac, Angelo Maiolino, Hiroyuki Takamatsu, Aurore Perrot, Mehmet Turgut, Tahamtan Ahmadi, Weiping Liu, Jianping Wang, Katherine Chastain, Jessica Vermeulen, Maria Krevvata, Lorena Lopez-Masi, Jodi Carey, Melissa Rowe, Robin Carson, Sonja Zweegman

引用次数: 0

Repurposing nirogacestat, a gamma secretase enzyme inhibitor in desmoid tumors. 一种γ分泌酶抑制剂硝格司他在硬纤维瘤中的应用。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-09-01 DOI: 10.1080/14796694.2025.2550826

Ghazal Tansir, Sameer Rastogi, Mrinal M Gounder

{"title":"Repurposing nirogacestat, a gamma secretase enzyme inhibitor in desmoid tumors.","authors":"Ghazal Tansir, Sameer Rastogi, Mrinal M Gounder","doi":"10.1080/14796694.2025.2550826","DOIUrl":"10.1080/14796694.2025.2550826","url":null,"abstract":"The gamma secretase (GS) enzyme controls cell-cell adhesion, neural stem cell proliferation, neo-angiogenesis, spinal maturation, and metabolism of amyloid precursor proteins (APP). Pathological production of abnormal amyloid-beta isoforms and senile plaques serves as the basis for pathogenesis of Alzheimer's disease (AD). GS enzyme inhibitors such as semagacestat and avagacestat were explored in AD but the studies were paused because of adverse events attributed to their influence on the Notch pathway.Crosstalk between Notch and Wnt signaling pathways created a potential role for GS inhibitors in the treatment of malignancies such as glioblastoma multiforme, pancreatic, and breast cancers. In a phase I study on nirogacestat among refractory solid malignancies, overall response rate (ORR) of 71.4% was observed in desmoid tumor (DT). The pivotal DeFi phase III trial established superiority of nirogacestat in terms of progression-free survival and ORR, reducing the likelihood of progression by 71%. Emphasis was placed on patient-reported outcomes (PRO) including the DT-specific tool, GOunder/Desmoid Tumor Research Foundation DEsmoid Symptom Scale (GODDESS).Nirogacestat received Food and Drug Administration (FDA) approval in November 2023 and European Commission approval in August 2025 for adults with progressing desmoid tumors (DT) who require systemic treatment. Further studies are underway to investigate other GS inhibitors such as AL-102 in the management of DT.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2985-2993"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490388/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144951221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world safety and efficacy of trastuzumab deruxtecan (T-DXd) in patients with HER2-positive/HER2-low metastatic breast cancer: a multicenter retrospective cohort study. 曲妥珠单抗德鲁西替康（T-DXd）治疗her2阳性/低her2转移性乳腺癌患者的安全性和有效性：一项多中心回顾性队列研究

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-09-14 DOI: 10.1080/14796694.2025.2560678

Elias Kotteas, Εmmanouil Panagiotou, Μaria Grammoustianou, Εvanthia Rousia, Αlexandros Kokkalis, Pantelis Dimaras, Theodora Papadimitriou, Georgios Gkoumas, Ioannis A Vathiotis, Dimitra T Stefanou, Κonstantinos Laschos, Helen Gogas, Dimitrios Mavroudis, Αthanasios Kotsakis, Αngelos Koutras, Nikolaos K Syrigos

{"title":"Real-world safety and efficacy of trastuzumab deruxtecan (T-DXd) in patients with HER2-positive/HER2-low metastatic breast cancer: a multicenter retrospective cohort study.","authors":"Elias Kotteas, Εmmanouil Panagiotou, Μaria Grammoustianou, Εvanthia Rousia, Αlexandros Kokkalis, Pantelis Dimaras, Theodora Papadimitriou, Georgios Gkoumas, Ioannis A Vathiotis, Dimitra T Stefanou, Κonstantinos Laschos, Helen Gogas, Dimitrios Mavroudis, Αthanasios Kotsakis, Αngelos Koutras, Nikolaos K Syrigos","doi":"10.1080/14796694.2025.2560678","DOIUrl":"10.1080/14796694.2025.2560678","url":null,"abstract":"Purpose: The efficacy of trastuzumab deruxtecan (T-DXd) has been demonstrated in large, phase III studies in HER2-positive (HER2+) and HER2-low metastatic breast cancer. Nevertheless, real-world data on T-DXd use are still limited.Methods: Patients with HER2+ or HER2-low metastatic breast cancer treated in six tertiary hospitals in Greece between September 2021 and May 2025 were included. Objective response rate, real-world progression-free survival (rwPFS), overall survival (rwOS), and safety were assessed.Results: Ninety-seven patients were included in the analysis; 49 had HER2+ and 48 had HER2-low disease. In the HER2+ cohort, median rwPFS was 14.9 months (95% Confidence Interval [CI], 10.97- not reached [NR]) and median rwOS was NR; rwPFS was shorter in patients with brain metastases (10.9 months vs 37.5 months, HR 3.28, p = 0.03). In the HER2-low cohort, rwPFS was 6.1 months (95% CI, 5.43-10.5) and rwOS was 14.1 months (95% CI, 9.6-NR). The rate of TRAEs was 41.1%; the rate of pneumonitis/interstitial lung disease was 6.7%. Dose interruptions and treatment discontinuation were reported in 4.4% and 1.1% cases, respectively.Conclusions: Our study confirms the efficacy and safety of T-DXd in daily clinical practice. Further research and longer patient follow-up are needed to elucidate optimal therapy sequencing.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3189-3196"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12520084/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145064037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

EGFR Exon 20 insertions in NSCLC: from biology to amivantamab, optimal treatment strategy and emerging therapeutics. EGFR外显子20在NSCLC中的插入：从生物学到阿米万他单抗，最佳治疗策略和新兴治疗方法。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-08-22 DOI: 10.1080/14796694.2025.2550927

Naoki Furuya

{"title":"EGFR Exon 20 insertions in NSCLC: from biology to amivantamab, optimal treatment strategy and emerging therapeutics.","authors":"Naoki Furuya","doi":"10.1080/14796694.2025.2550927","DOIUrl":"10.1080/14796694.2025.2550927","url":null,"abstract":"EGFR exon 20 insertion (Ex20ins) mutations are the third most frequent EGFR mutations, which accounts for around 4-12% of EGFR mutations in advanced NSCLC. It is well known that conventional EGFR-TKI monotherapy is less effective for patients with EGFR Ex20ins. Amivantamab is the first in class drug for established standard therapy of advanced stage NSCLC harboring Ex20ins mutations. Amivantamab has the following four unique mechanisms of action for Ex20ins mutated NSCLC; 1) dual-blocking receptor and inhibition of signaling pathway of EGFR and cMET, 2) antibody-dependent cellular cytotoxicity (ADCC) by NK cells, 3) antibody-dependent cellular trogocytosis (ADCT) by macrophages, 4) lysosomal receptor internalization and subsequent degradation. Amivantamab, in combination with carboplatin plus permetexed, was established in the PAPILLON study. However, it is unclear regarding the efficacy and CNS penetration of amivantamab for patients with Ex20ins mutations involving CNS/brain metastases. For patients with A763_Y764insFQEA mutation involving serious brain metastases, conventional EGFR-TKI might be an important treatment option. There are four phase III studies ongoing investigating new EGFR-TKI monotherapies or combination therapy with cytotoxic chemotherapy for EGFR Ex20ins mutations in the first-line setting. This review comprehensively summarized the biology and clinical characteristics of Ex20ins mutations and provide cutting-edge information and future perspectives.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2995-3004"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490370/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144951372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting. 布鲁顿酪氨酸激酶抑制剂治疗套细胞淋巴瘤的现实世界治疗模式在社区肿瘤学设置。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-09-07 DOI: 10.1080/14796694.2025.2554354

Bijal D Shah, Mei Xue, Wesley Furnback, Keri Yang

{"title":"Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting.","authors":"Bijal D Shah, Mei Xue, Wesley Furnback, Keri Yang","doi":"10.1080/14796694.2025.2554354","DOIUrl":"10.1080/14796694.2025.2554354","url":null,"abstract":"Aims: This study examines United States real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns, duration, and adherence in mantle cell lymphoma (MCL) patients.Materials & methods: A retrospective analysis of electronic medical records for patients with MCL who initiated a BTKi between January 2019 and November 2021 was conducted. Patients were followed ≥ 6 months, examining baseline characteristics and outcomes including treatment duration and adherence.Results: 402 patients initiated acalabrutinib (n = 161), ibrutinib (n = 197), or zanubrutinib (n = 44). The zanubrutinib group demonstrated significantly longer median treatment duration (292 days) compared with acalabrutinib (259 days) and ibrutinib (149 days; P < 0.01) and displayed significantly higher adherence to treatment.Conclusions: In this study, zanubrutinib group experienced significantly longer treatment durations and higher adherence compared with the acalabrutinib and ibrutinib groups.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3043-3049"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490371/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145014984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How I treat Ph+ acute lymphoblastic leukemia. 如何治疗Ph+急性淋巴细胞白血病。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-09-07 DOI: 10.1080/14796694.2025.2556647

Melanie Castro-Mollo, Daniel J DeAngelo, Marlise R Luskin

{"title":"How I treat Ph+ acute lymphoblastic leukemia.","authors":"Melanie Castro-Mollo, Daniel J DeAngelo, Marlise R Luskin","doi":"10.1080/14796694.2025.2556647","DOIUrl":"10.1080/14796694.2025.2556647","url":null,"abstract":"Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is characterized by the BCR:ABL1 fusion gene which produces a constitutively active tyrosine kinase which drives disease pathogenesis and is associated with resistance to conventional chemotherapy. Intensive cytotoxic chemotherapy followed by allogeneic hematopoietic stem cell transplantation (HSCT), the historical treatment paradigm for Ph+ ALL, was associated with poor outcomes. The introduction of inhibitors of ABL1 revolutionized the treatment of Ph+ ALL. Imatinib, the first BCR:ABL1 tyrosine kinase inhibitor (TKI), significantly improved survival, and was followed by more potent TKIs (dasatinib, nilotinib, and ponatinib) with activity also against resistance mutations. The introduction of blinatumomab, a CD19-CD3 bispecific T-cell engager, has further transformed the treatment of Ph+ ALL, allowing some patients to be treated without cytotoxic chemotherapy and/or HSCT. Still, HSCT remains an essential treatment option for select high-risk cases. Ongoing investigation focuses on more accurately identifying clinical and genetic features which predict for systemic or central nervous system relapse and determining the most effective approach to successfully risk-adapt therapy, including appropriate allocation to HSCT. This review highlights recent advances in treatment, emphasizing the importance of TKIs, the emerging role of immunotherapy, and the evolving position of HSCT in the management of Ph+ ALL.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3139-3149"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12520080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145014917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0